Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patie...
OncoC4 Inc., a late clinical stage biopharmaceutical company, announced first participant's dosing following the clearance of the Investigational New Dru...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, \announced a strategic collaboration with Precision Health Research...
Innovaccer Inc., a leading healthcare AI company, and Infinia Technologies, a next-generation digital transformation company and a subsidiary of Sirius I...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis...
The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled wit...
Mayo Clinic announces a gift of $75 million from the Thomas and Elizabeth Grainger family to support Bold. Forward. Unbound. in Rochester, Mayo Clinic's ...
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nord...
Study conducted in collaboration with the Neuroregeneration Institute at McLean Hospital Autologous neuronal cell therapy for Parkinson’s diseas...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
© 2026 Biopharma Boardroom. All Rights Reserved.
